Psychosocial functioning after discontinuation of long-term growth hormone treatment in girls with Turner syndrome.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

It is common practice in the case of Turner syndrome (TS) to treat short stature with GH treatment and to induce puberty with estrogens at an age as close to normal puberty as possible.

This approach in most cases leads to a height in the normal range in childhood, adolescence, and adulthood in TS.

Who Took Part

The study group was 50 women.

PubMed indexes the participants as young children and children, women only.

After discontinuation of long-term GH treatment, these 50 girls were evaluated for psychosocial functioning at a mean age of 18.8 (0.3) years.

How the Study Was Run

In design terms this was a randomized and multicenter study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

More than one site took part, so the women came from several places.

What Was Measured

In the present study, the researchers evaluated psychosocial functioning in a group of 50 women with TS, after reaching final height in two multicenter GH trials.

After a mean GH treatment duration of 7.1 (0.4) years, mean final height (ref. normal girls) was FH1.2 (0.2) SD score.

Topics PubMed links to this paper include Adaptation, Psychological, Body Image, Depression, Human Growth Hormone, Logistic Models, Self Concept and Social Behavior.

What This Means in Plain Language

The paper is a randomized and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 50 women.

The publication is from 2005 (Hormone research), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.